Geriatrik Onkoloji Hastalarında Kötü Prognoz Etkeni: Polifarmasi ve Yönetimi
Geriatrik onkoloji hastaları, yaşlanma ile ilişkili birçok komorbidite ile karşılaşmaktadır. Bu komorbiditeler, çoklu ilaç kullanımı olarak tanımlanan polifarmasiye neden olmaktadır. Polifarmasi; tedavi ve bakım sürecini zorlaştırarak, hastaların yaşam kalitesini azaltmaktadır. Aynı zamanda kanserin prognozunu olumsuz etkileyerek mortalite riskini arttırmaktadır. Bu denli kompleks bir sürecin değerlendirilmesi ve yönetimi, multidisipliner bir yaklaşım gerektirmektedir. Bu makalede; geriatrik onkoloji hastalarında polifarmasinin değerlendirilmesi, polifarmasinin komplikasyonları, ilaç-ilaç ve ilaç-besin etkileşimleri, onkolojik prognoza etkisi ve sürecin etkin bir şekilde yönetilmesi ele alınmıştır.
FACTOR OF POOR PROGNOSIS IN GERIATRIC ONCOLOGY PATIENTS: POLYPHARMACY AND MANAGEMENT
Geriatric oncology patients encounter many comorbidities associated with aging. These comorbidities cause multiple drug use, which is defined as polypharmacy. Polypharmacy complicates the treatment and care process and reduces the quality of life of patients. At the same time, it increases the risk of mortality by negatively affecting the prognosis of cancer. Evaluation and management of such a complex process requires a multidisciplinary approach. In this article; Evaluation of polypharmacy in geriatric oncology patients, complications of polypharmacy, drug-drug and drug-food interactions, its effect on oncological prognosis and effective management of the process are discussed.
___
- 1. Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM. Polypharmacy and
potentially inappropriate medication use in geriatric oncology. Journal of geriatric
oncology. 2016;7(5):346-353.
- 2. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy:
misleading, but manageable. Clinical interventions in aging. 2008;3(2):383.
- 3. Veehof LJG, Stewart RE, Haaijer-Ruskamp FM, Jong BMD. The development of
polypharmacy. A longitudinal study. Family practice. 2000;17(3):261-267.
- 4. Bikowski RM, Ripsin CM, Lorraine VL. Physician‐patient congruence regarding
medication regimens. Journal of the American Geriatrics Society. 2002;49(10):1353-
1357.
- 5. Assari S, Helmi H, Bazargan M. Polypharmacy in African American adults: a national
epidemiological study. Pharmacy. 2019;7(2):33.
- 6. Kapucu S. Geriatri Hemşireliği. Ankara: Hipokrat Kitabevi; 2019.
- 7. Midão L, Giardini A, Menditto E, Kardas P, Costa E. Polypharmacy prevalence
among older adults based on the survey of health, ageing and retirement in
Europe. Archives of gerontology and geriatrics. 2018;78:213-220.
- 8. Öztürk Z, Uğraş KG. Yaşlı hastalarda ilaç kullanımı ve polifarmasi. İzmir Tepecik
Eğitim ve Araştırma Hastanesi Dergisi. 2017;27(2):103-108.
- 9. Erbay Ö. Yaşlılarda Büyüyen''Polifarmasi''Sorunu: Hemşirelerin Rolü. Türkiye
Klinikleri Hemşirelik Bilimleri Dergisi. 2018;10(3):222-227.
- 10. Nightingale G, Skonecki E, Boparai MK. The impact of polypharmacy on patient
outcomes in older adults with cancer. The Cancer Journal. 2017;23(4):211-218.
- 11. Prithviraj GK, Koroukian S, Margevicius S, Berger NA, Bagai R, Owusu C. Patient
characteristics associated with polypharmacy and inappropriate prescribing of
medications among older adults with cancer. Journal of geriatric
oncology.2012;3(3):228-237.
- 12. Kierner KA, Weixler D, Masel EK, Gartner V, Watzke HH. Polypharmacy in the
terminal stage of cancer. Supportive Care in Cancer.2016;24(5):2067-2074.
- 13. Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A. Evaluation of a
Pharmacist-Led Medication Assessment Used to Identify Prevalence of and
Associations With Polypharmacy and Potentially Inappropriate Medication Use
Among Ambulatory Senior Adults With Cancer. Journal of Clinical
Oncology.2015;33(13):1453-1459.
- 14. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with
cancer. Journal of Clinical Oncology.2007;25(14):1824-1831.
- 15. Whitman AM, DeGregory KA, Morris AL, Ramsdale EE. A comprehensive look at
polypharmacy and medication screening tools for the older cancer patient. The
oncologist. 2016;21(6):723-730.
- 16. Lichtman SM. Polypharmacy: geriatric oncology evaluation should become
mainstream. Journal of Clinical Oncology. 2015;33(13):1422-1423.
- 17. Kerry Z. Yaşlılarda doğru ilaç kullanımı. Ege tıp dergisi. 2015:54.
- 18. 2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM,
Semla TP, Steinman M, Beizer J, Brandt N et al. American Geriatrics Society 2019
updated AGS Beers Criteria® for potentially inappropriate medication use in older
adults. Journal of the American Geriatrics Society. 2019;67(4):674-694.
- 19. Steinman MA, Fick DM. Using wisely: a reminder on the proper use of the American
Geriatrics Society Beers Criteria®. Journal of the American Geriatrics Society.
2019;67(4):644-646.
- 20. Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially
inappropriate Prescriptions): application to acutely ill elderly patients and comparison
with Beers’ criteria. Age and ageing. 2008;37(6):673-679.
- 21. Blanco‐Reina E, Ariza‐Zafra G, Ocaña‐Riola R, León‐Ortiz M. 2012 American
Geriatrics Society Beers Criteria: Enhanced Applicability for Detecting Potentially
Inappropriate Medications in E uropean Older Adults? A Comparison with the
Screening Tool of Older Person's Potentially Inappropriate Prescriptions. Journal of
the American Geriatrics Society. 2014;62(7):1217-1223.
- 22. Oliveira MG, Amorim WW, de Jesus SR, Heine JM, Coqueiro HL, Passos LCS. A
comparison of the B eers and STOPP criteria for identifying the use of potentially
inappropriate medications among elderly patients in primary care. Journal of
evaluation in clinical practice. 2015;21(2):320-325.
- 23. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P.
STOPP/START criteria for potentially inappropriate prescribing in older people:
version 2. Age and ageing. 2014;44(2):213-218.
- 24. O’Mahony D, Gallagher P, Ryan C, Byrne S, Hamilton H, Barry P et al. STOPP &
START criteria: a new approach to detecting potentially inappropriate prescribing in
old age. European Geriatric Medicine. 2010;1(1):45-51.
- 25. Yeşil Y, Cankurtaran M, Kuyumcu ME. Polifarmasi. Klinik Gelişim. 2012;25(3):18-23.
- 26. Beğer T, Suna Erdinçler D, Altıparmak MR. Geriatrik Hasta ve Sorunları. İstanbul:
Doyuran Matbaası; 2011.
- 27. Elkin N. Yaşlılarda Polifarmasi ve Akılcı İlaç Kullanımına Aile Hekimliği
Yaklaşımı. İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi. 2020;(11):279-290.
- 28. Fulton MM, Riley Allen E. Polypharmacy in the elderly: a literature review. Journal of
the American Academy of Nurse Practitioners.2005;17(4):123-132.
- 29. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in
elderly. Expert Opinion on Drug Safety. 2014;13(1):57–65.
- 30. Frazier SC. Health outcomes and polypharmacy in elderly individuals: An integrated
literature review. Journal of Gerontological Nursing. 2005;31(9):4–11.
- 31. Alpert PT, Gatlin T. Polypharmacy in older adults. Home healthcare now.
2015;33(10):524-529.
- 32. Maroñas-Jiménez L, Castellanos-González M, Sanz Bueno J, Vanaclocha Sebastián F.
Erosiones y úlceras acrales: manifestación precoz de toxicidad aguda grave por
metrotexato. Actas Dermo-Sifiliográficas. 2014;105(3):322-323.
- 33. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of a
salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with
rheumatoid arthritis. European journal of clinical pharmacology. 1992;42(2):121-125.
- 34. Zarychanski R, Wlodarczyk K, Ariano R, Bow E. Pharmacokinetic interaction
between methotrexate and piperacillin/tazobactam resulting in prolonged toxic
concentrations of methotrexate. Journal of Antimicrobial Chemotherapy.
2006;58(1):228-230.
- 35. Koerber H, Gross WL, Iven H. Do steroids influence low dose methotrexate
pharmacokinetics?. The Journal of rheumatology. 1994;21(6):1170-1172.
- 36. Delafuente JC. Understanding and preventing drug interactions in elderly
patients. Critical reviews in oncology/hematology. 2003;48(2):133-143.
- 37. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and
chemotherapeutic drugs. The Lancet Neurology. 2003;2(7):404-409.
- 38. Bermúdez M, Fuster JL, Llinares E, Galera A, Gonzalez C. Itraconazole-related
increased vincristine neurotoxicity: case report and review of literature. Journal of
Pediatric Hematology/Oncology. 2005;27(7):389-392.
- 39. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of
cytotoxic drugs. Cancer treatment reviews. 2004;30(2):181-191.
- 40. Shah SR, Martin R, Dowell JE, Ussery SMG. Comparison of the
5‐Fluorouracil‐Warfarin and Capecitabine‐Warfarin Drug
Interactions. Pharmacotherapy: The Journal of Human Pharmacology and Drug
Therapy. 2010;30(12):1259-1265.
- 41. Juurlink D. Revisiting the drug interaction between tamoxifen and SSRI
antidepressants. BMJ. 2016:354.
- 42. Levêque D, Becker G, Bilger K, Natarajan-Amé S. Clinical pharmacokinetics and
pharmacodynamics of dasatinib. Clinical Pharmacokinetics. 2020;59(7):849-856.
- 43. Ikeda H, Murakami T, Takano M, Usui T, Kihira K. Pharmacokinetic interaction on
valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic
patient. British journal of clinical pharmacology. 2005;59(5):593-597.
- 44. Couderc LJ, Stelianides S, Frachon I, Stern M, Epardeau B, Baumelou E et al.
Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five
cases. Respiratory medicine. 1999;93(1):65-68.
- 45. Johnson EJ, MacGowan AP, Potter MN, Stockley RJ, White LO, Slade RR, Reeves
DS. Reduced absorption of oral ciprofloxacin after chemotherapy for haematological
malignancy. Journal of Antimicrobial Chemotherapy. 1990;25(5):837-842.
- 46. Giunta G. Warfarin–5-FU interactions. Annals of oncology. 2006;17(1):176.
- 47. Van Leeuwen RWF, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg
JG. Potential drug interactions in cancer therapy: a prevalence study using an
advanced screening method. Annals of oncology. 2001;22(10):2334-2341.
- 48. de Jonge ME, Huitema A.D, van Dam SM, Beijnen JH, Rodenhuis S. Significant
induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer
chemotherapy and pharmacology. 2005;55(5):507-510.
- 49. Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications
and management. The lancet oncology. 2011;12(13):1249-1257.
- 50. Nightingale G, Hajjar E, Guo K, Komura S, Urnoski E, Sendecki J et al. A
pharmacist-led medication assessment used to determine a more precise estimation of
the prevalence of complementary and alternative medication (CAM) use among
ambulatory senior adults with cancer. Journal of geriatric oncology. 2015;6(5):411-417.
- 51. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the
need for an interdisciplinary approach to side‐effect management 1. Journal of
clinical pharmacy and therapeutics. 2007;32(2):169-175.
- 52. Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C. Potential drug-drug and herb-drug
interactions in patients with cancer: a prospective study of medication
surveillance. Journal of oncology practice. 2017;13(7):613-622.
- 53. Chen LJ, Nguyen TNM, Chang-Claude J, Hoffmeister M, Brenner H, Schöttker B.
Association of polypharmacy with colorectal cancer survival among older
patients. The oncologist. 2021;26(12):2170-2180.
- 54. Jørgensen TL, Herrstedt J. The influence of polypharmacy, potentially inappropriate
medications, and drug interactions on treatment completion and prognosis in older
patients with ovarian cancer. Journal of geriatric oncology. 2020;11(4):593-602.
- 55. Loh KP, Soto Pérez de Celis E, Duberstein PR, Culakova E, Epstein RM, Xu H et al.
Patient and caregiver agreement on prognosis estimates for older adults with advanced
cancer. Cancer. 2021;127(1):149-159.
- 56. Mangoni AA, Jackson SH. Age‐related changes in pharmacokinetics and
pharmacodynamics: basic principles and practical applications. British journal of
clinical pharmacology. 2004;57(1):6-14.
- 57. Whitman A, DeGregory K, Morris A, Mohile S, Ramsdale E. Pharmacist-led
medication assessment and deprescribing intervention for older adults with cancer and
polypharmacy: a pilot study. Supportive Care in Cancer. 2018;26(12):4105-4113.
- 58. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D et al. Reducing
inappropriate polypharmacy: the process of deprescribing. JAMA internal medicine.
2015;175(5):827-834.
- 59. Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA et al.
International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of
chemotherapy in older patients—an analysis of the medical literature. Journal of
clinical oncology. 2007;25(14):1832-1843.
- 60. Puts MT, Costa-Lima B, Monette J, Girre V, Wolfson C, Batist G, Bergman H.
Medication problems in older, newly diagnosed cancer patients in Canada: how
common are they?. Drugs & aging. 2009;26(6):519-536.
- 61. Kaya H, Turan N, Çulha Y, Aydın GÖ. Yaşlı Bireylerde İlaç Yönetiminde Hemşirenin
Rolü. JAREN/Hemşirelik Akademik Araştırma Dergisi. 2018;4(2):120-126.
- 62. Karadakovan A. Yaşlı sağlığı ve bakım. Ankara: Akademisyen Kitabevi; 2014.